Articles

ABOUT AUTHORS:
Md. Yaqub Khan*, Poonam Gupta, Dr. Dipendu Goswami, Bipin Bihari, Vikas Kumar Verma
Saroj Institute of Technology & Management,
Ahimamau P.O. Arjunganj Sultanpur  Road,
Lucknow  -226002
*khanishaan16@yahoo.com

ABOUT AUTHORS:
Mahaveer Prasad Kabra*, Sanjay Singh Bhandari, Shakti Singh, Paresh Mohan.
Kota College of Pharmacy, SP-1,
RIICO Industrial Area, Ranpur,
Jhalawar road, Kota, Rajasthan, India – 324009
*sanskarkabra@gmail.com

ABOUT AUTHOR:
Shalu Shukla
M.Pharmacy
Bahra University
shukla5828@gmail.com

ABSTRACT
The use of nanotechnology in medicine and more specifically drug delivery is set to spread rapidly. Currently many substances are under investigation for drug delivery and more specifically for cancer therapy. Interestingly pharmaceutical sciences are using nanoparticles to reduce toxicity and side effects of drugs and up to recently did not realize that carrier systems themselves may impose risks to the patient. The kind of hazards that are introduced by using nanoparticles for drug delivery are beyond that posed by conventional hazards imposed by chemicals in classical delivery matrices. For nanoparticles the knowledge on particle toxicity as obtained in inhalation toxicity shows the way how to investigate the potential hazards of nanoparticles. The toxicology of particulate matter differs from toxicology of substances as the composing chemical(s) may or may not be soluble in biological matrices, thus influencing greatly the potential exposure of various internal organs. This may vary from a rather high local exposure in the lungs and a low or neglectable exposure for other organ systems after inhalation. However, absorbed species may also influence the potential toxicity of the inhaled particles. For nanoparticles the situation is different as their size opens the potential for crossing the various biological barriers within the body. From a positive viewpoint, especially the potential to cross the blood brain barrier may open new ways for drug delivery into the brain. In addition, the nanosize also allows for access into the cell and various cellular compartments including the nucleus. A multitude of substances are currently under investigation for the preparation of nanoparticles for drug delivery, varying from biological substances like albumin, gelatin and phospholipids for liposomes, and more substances of a chemical nature like various polymers and solid metal containing nanoparticles. It is obvious that the potential interaction with tissues and cells, and the potential toxicity, greatly depends on the actual composition of the nanoparticle formulation. This paper provides an overview on some of the currently used systems for drug delivery.

[adsense:336x280:8701650588]

ABOUT AUTHORS:
*Anyonyya Mallam, surendar Angothu
Department of Pharmacognosy,
Vathsalya College of Pharmacy, Bhongir,
Nalgonda (Dist), Andhra Pradesh –  508116, India
*anyonyya1688@gmail.com

About Author:
Sujatha Ramasamy
Scientist-B, Technology Information,
Forecasting and Assessment Council (TIFAC)
New Delhi, India.
sujathar23@gmail.com

ABOUT AUTHORS:
Bhaskar Ingole, Shradha Tiwari*
SSS. Indira College of pharmacy,
Vishnupuri, Nanded
*Shraddha.life10@gmail.com

ABSTRACT:
Pulsatile drug delivery aims to release drugs on a programmed pattern means at appropriate time and/or at appropriate site of action. Pulsatile Drug Delivery Systems are gaining a lot of interest as they deliver the drug at the right place at the right time and in the right amount, thus providing spatial and temporal delivery and increasing patient compliance These systems are designed according to the circadian rhythm of the body. Pulsatile release of the drugs is used where a constant drug release is not desired.Gastric retentive systems, systems where the drug is released following a programmed lag phase, chronopharmaceutical drug delivery systems matching human circadian rhythms, multiunit or multilayer systems with various combinations of immediate and sustained-release preparation, are all classified under pulsatile drug delivery systems. On the other hand, site-controlled release is usually controlled by factors such as the pH of the target site, the enzymes present in the intestinal tract and the transit time/pressure of various parts of the intestine. In this review, recent patents on pulsatile drug delivery of oral dosage forms are summarized and discussed.

About Author:
Zehira Nazir
Master’s In Clinical Biochemistry
University Of Kashmir
zzehra275@gmail.com

ABOUT AUTHORS:
Harshil R. Patel*, Sejal K. Patel
Department of Quality Assurance,
S. K. Patel College of Pharmaceutical Education and Research,
Ganpat University, Ganpat Vidyanagar – 384012, Mehsana, Gujarat, India.
*harshil285@gmail.com